Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dirk van Lier

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Current Opinion in Critical Care|April 26, 2021
Circulating biomarkers to assess cardiovascular function in critically illDirk van Lier, Peter Pickkers
Journal of Critical Care|July 23, 2023
Associations of dipeptidyl-peptidase 3 with short-term outcome in a mixed admission ICU-cohortDirk van Lier, Remi Beunders, Matthijs Kox, et al.
European Journal of Anaesthesiology|February 1, 2022
The value of bioactive adrenomedullin and dipeptidyl peptidase 3 to predict short-term unfavourable outcomes after cardiac surgery: A prospective cohort studyDirk van Lier, Remi Beunders, Matthijs Kox, et al.
Biochimie|June 25, 2018
Experimental human endotoxemia as a model of systemic inflammationDirk van Lier, Christopher Geven, Guus P Leijte, et al.
ERJ Open Research|March 19, 2021
Increased blood angiotensin converting enzyme 2 activity in critically ill COVID-19 patientsDirk van Lier, Matthijs Kox, Karine Santos, et al.
Annals of Intensive Care|June 14, 2024
Impaired angiotensin II signaling in septic shockAdrien Picod, Bruno Garcia, Dirk Van Lier, et al.
British Journal of Clinical Pharmacology|June 2, 2018
Safety, tolerability and pharmacokinetics/pharmacodynamics of the adrenomedullin antibody adrecizumab in a first-in-human study and during experimental human endotoxaemia in healthy subjectsChristopher Geven, Dirk van Lier, Alice Blet, et al.
Mabs|May 21, 2026
Safety, tolerability, and pharmacokinetics/-dynamics of the dipeptidyl peptidase 3-inhibiting antibody Procizumab in a first-in-human trialDirk van Lier, Louis Mourisse, Hákon Hollander, et al.
ERJ Open Research|January 11, 2023
Circulating dipeptidyl peptidase 3 and bio-adrenomedullin levels are associated with impaired outcomes in critically ill COVID-19 patients: a prospective international multicentre studyDirk van Lier, Benjamin Deniau, Karine Santos, et al.
Scientific Reports|June 18, 2024
Preclinical and first-in-human safety studies on a novel magnetism-based haemofiltration methodNicole Waalders, Dirk van Lier, Jelle Gerretsen, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Current Opinion in Critical Care|April 26, 2021
Circulating biomarkers to assess cardiovascular function in critically illDirk van Lier, Peter Pickkers
Journal of Critical Care|July 23, 2023
Associations of dipeptidyl-peptidase 3 with short-term outcome in a mixed admission ICU-cohortDirk van Lier, Remi Beunders, Matthijs Kox, et al.
European Journal of Anaesthesiology|February 1, 2022
The value of bioactive adrenomedullin and dipeptidyl peptidase 3 to predict short-term unfavourable outcomes after cardiac surgery: A prospective cohort studyDirk van Lier, Remi Beunders, Matthijs Kox, et al.
Biochimie|June 25, 2018
Experimental human endotoxemia as a model of systemic inflammationDirk van Lier, Christopher Geven, Guus P Leijte, et al.
ERJ Open Research|March 19, 2021
Increased blood angiotensin converting enzyme 2 activity in critically ill COVID-19 patientsDirk van Lier, Matthijs Kox, Karine Santos, et al.
Annals of Intensive Care|June 14, 2024
Impaired angiotensin II signaling in septic shockAdrien Picod, Bruno Garcia, Dirk Van Lier, et al.
British Journal of Clinical Pharmacology|June 2, 2018
Safety, tolerability and pharmacokinetics/pharmacodynamics of the adrenomedullin antibody adrecizumab in a first-in-human study and during experimental human endotoxaemia in healthy subjectsChristopher Geven, Dirk van Lier, Alice Blet, et al.
Mabs|May 21, 2026
Safety, tolerability, and pharmacokinetics/-dynamics of the dipeptidyl peptidase 3-inhibiting antibody Procizumab in a first-in-human trialDirk van Lier, Louis Mourisse, Hákon Hollander, et al.
ERJ Open Research|January 11, 2023
Circulating dipeptidyl peptidase 3 and bio-adrenomedullin levels are associated with impaired outcomes in critically ill COVID-19 patients: a prospective international multicentre studyDirk van Lier, Benjamin Deniau, Karine Santos, et al.
Scientific Reports|June 18, 2024
Preclinical and first-in-human safety studies on a novel magnetism-based haemofiltration methodNicole Waalders, Dirk van Lier, Jelle Gerretsen, et al.
Pageof 2